Streetbeat News

Price Targets

ALLO

Citigroup analyst Samantha Semenkow maintains a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and raises the price target from $7 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:50 pm

EXPE

Citigroup analyst Ronald Josey maintains a Neutral rating on Expedia Group (NASDAQ:EXPE) and raises the price target from $140 to $145.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:47 pm

GDRX

Citigroup analyst Daniel Grosslight maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) but lowers the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:45 pm

FUN

Citigroup analyst James Hardiman maintains a Buy rating on Six Flags Entertainment (NYSE:FUN) but lowers the price target from $64 to $61.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:44 pm

CPRX

Citigroup analyst Samantha Semenkow maintains a Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises the price target from $27 to $31.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:42 pm

YETI

Citigroup analyst Wendy Nicholson maintains a Buy rating on YETI Holdings and raises the price target from $47 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:41 pm

NUS

Citigroup analyst Chasen Bender maintains a Neutral rating on Nu Skin Enterprises (NYSE:NUS) but lowers the price target from $14 to $11.5.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:37 pm

SANA

Citigroup analyst Samantha Semenkow maintains a Buy rating on Sana Biotechnology (NASDAQ:SANA) and raises the price target from $8 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:36 pm

IRWD

Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Ironwood Pharmaceuticals (NASDAQ:IRWD) but lowers the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:30 pm

AVT

Wells Fargo analyst Joseph Quatrochi maintains an Underweight rating on Avnet (NASDAQ:AVT) but raises the price target from $40 to $45.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:29 pm